Almirall's H1 Results 2014: Continued Growth Acceleration

• Market share gains for Eklira® in all key geographies
• Platforms of Growth represent 44% of Net Sales after growing 63% vs H1 2013
• Acceleration of Net Sales (+17.4%) and EBITDA (+46.9%)
• CHMP Opinion for aclidinium+formoterol combination in EU expected in late Q3

Eduardo Sanchiz, Chief Executive Officer, commented:

“The positive trend seen in Q1 has continued in Q2. It is especially pleasing to see the performance of Platforms of Growth (63% growth year on year and now representing 44% of sales), and the continuous strong gross margin evolution. This, combined with a lower expense trend in the second half of the year, will drive an expected acceleration of Normalized Net Income growth through 2014 and gives us the confidence to reiterate our full-year guidance.

I'm also pleased that after the meeting this month with the FDA, regarding the combination of aclidinium+formoterol, we have agreed and have clarity on next steps”.

For full access, please click here.

Help employers find you! Check out all the jobs and post your resume.